As an antagonist of IL-33/ST2, sST2 plays a negative role in CRC tumor growth by inhibiting IL-33-mediated angiogenesis, Th1 and Th2 responses, macrophage infiltration, and M2a polarization [231,236]. This evidence concerns the gene IL33 and neoplasm.